Intermuscular Coherence as a Biomarker for ALS (NCT05104710)
Intermuscular Coherence: A Biomarker for Early Diagnosis and Follow-up of ALS
๐ฉบ Plain-English Summary (8th-Grade Level)
The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-ฮฒฮณ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. 2. Characterize IMC-ฮฒฮณ in neurotypical subjects by age, sex, race, and ethnicity. 3. Follow a cohort of ALS patients longitudinally to determine if IMC-ฮฒฮณ changes with ALS disease progression and whether such changes correlate with functional and clinical scores, or survival.
Who can join: Review the eligibility criteria below.
Location: University of California Center for Clinical Research โ Irvine, California
Age range: 20 Years to 90 Years
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (4 Sites)
- University of California Center for Clinical Research โ Irvine, California
- University of Miami Miller School of Medicine โ Miami, Florida
- Massachusetts General Hospital โ Boston, Massachusetts
- Washington University Medical Center โ St Louis, Missouri
๐ Contact the Study Coordinator
Phone: (773) 795-9908
Email: serdarmd@bsd.uchicago.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Amyotrophic Lateral Sclerosis
- Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) โ Toronto, Ontario
- Regulatory T Cells for Amyotrophic Lateral Sclerosis โ New York, New York
- Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) โ Phoenix, Arizona
- TRIAL READY (Clinical Trial Readiness) โ Miami, Florida
- Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment โ Phoenix, Arizona
- Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS โ New York, New York
Explore by condition: All Amyotrophic Lateral Sclerosis clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.